Research Article
Prognostic Significance of Serum Uric Acid and Gamma-Glutamyltransferase in Patients with Advanced Gastric Cancer
Table 1
Demographics and clinicopathologic characteristics of patients with advanced gastric cancer.
| | Primary cohort | | Validation cohort | | | % | | % |
| | Sex | Female | 41 | 22.8 | 15 | 25.0 | | | Male | 139 | 77.2 | 45 | 75.0 | | Age (years) | Median/range | 60.31/(24.00-88.00) | 57.52/(24.00-77.00) | | NLR | Median/range | 4.61/(0.21-76.29) | 5.43/(0.33-76.29) | | PLR | Median/range | 207.04/(46.0-1156.4) | 211.00/(63.50-632.14) | | LMR | Median/range | 4.57/(0.22-84.00) | 4.36/(0.43-84.00) | | D-D | Median/range | 805.01/(0.22-12690.00) | 1367.32/(0.22-12690.00) | | FIB | Median/range | 3.85/(0.71-14.00) | 4.06/(1.91-14.00) | | ALB | Median/range | 36.22/(16.30-59.84) | 36.24/(21.30-59.84) | | Cholesterol | Median/range | 4.54/(0.82-13.03) | 4.39/(0.82-6.87) | | Triglyceride | Median/range | 1.10/(0.29-6.83) | 1.16/(0.63-1.77) | | HDL | Median/range | 1.16/(0.28-2.47) | 1.06/(0.36-2.08) | | GGT | Median/range | 32.83/(4.00-1076.00) | 23.26/(6.00-169.00) | | UA | Median/range | 255.94/(56.00-743.53) | 269.53/(81.00-634.00) | | CEA | Median/range | 66.61/(0.20-1000.00) | 50.66/(0.20-1000) | | CA199 | Median/range | 195.51/(0.60-1000.00) | 191.22/(0.60-1000.00) | | BMI | Median/range | 22.24/(12.44-30.85) | 22.23/(12.44-28.22) | | Histologic differentiation | Moderate/well | 20 | 11.1 | 7 | 11.7 | | Poor | 160 | 88.9 | 53 | 88.3 | | Tumor location | L | 143 | 79.4 | 49 | 81.7 | | | M | 20 | 11.1 | 6 | 10.0 | | | U | 17 | 9.4 | 5 | 8.3 | | Her-2 | Negative | 174 | 96.7 | 56 | 93.3 | | | Positive | 6 | 3.3 | 4 | 6.7 | | Family history | No | 175 | 97.2 | 58 | 96.7 | | | Yes | 5 | 2.8 | 2 | 3.3 | | Surgery | No | 122 | 67.8 | 35 | 58.3 | | | Yes | 58 | 67.8 | 25 | 41.7 | | Chemotherapy | No | 40 | 22.2 | 4 | 6.7 | | | Yes | 140 | 77.8 | 56 | 93.3 | | Radiotherapy | No | 167 | 92.8 | 56 | 93.3 | | | Yes | 13 | 92.8 | 4 | 6.7 | | Target therapy | No | 163 | 90.6 | 52 | 86.7 | | | Yes | 17 | 9.4 | 8 | 13.3 | | Peritoneal metastasis | No | 141 | 78.3 | 48 | 80.0 | | | Yes | 39 | 21.7 | 12 | 20.0 | | Liver metastasis | No | 135 | 75.0 | 46 | 76.7 | | | Yes | 45 | 25.0 | 14 | 23.3 | | Bone metastasis | No | 171 | 95.0 | 56 | 93.3 | | | Yes | 9 | 5.0 | 4 | 6.7 | | Lung metastasis | No | 168 | 93.3 | 53 | 88.3 | | | Yes | 12 | 6.7. | 7 | 11.7. | | Ovary metastasis | No | 172 | 95.6 | 57 | 95.0 | | | Yes | 8 | 4.4 | 3 | 5.0 | | Distant lymph node metastasis | No | 100 | 55.6 | 35 | 58.3 | | | Yes | 80 | 44.4 | 25 | 41.7 | | Histologic type | Adenocarcinoma | 151 | 83.9 | 54 | 90.0 | | | Others | 29 | 16.1 | 6 | 10.0 | | T stage | T3 | 43 | 23.9 | 10 | 16.7 | | | T4 | 137 | 76.1 | 50 | 83.3 | | N stage | N2 | 33 | 18.3 | 15 | 25.0 | | | N3 | 147 | 81.7 | 45 | 75.0 | | TNM stage | III stage | 50 | 27.8 | 13 | 21.7 | | | IV stage | 130 | 72.2 | 47 | 78.3 |
|
|
Abbreviations: AGC: advanced gastric cancer; NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; LMR: lymphocyte to monocyte ratio; D-D: D-dimer; FIB: fibrinogen; ALB: albumin; HDL: high-density lipoprotein; GGT: gamma-glutamyltransferase; UA: uric acid; CEA: carcino-embryonic antigen; BMI: body mass index.
|
